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Background: To compare the patients with primary colorectal carcinoma (CRC) and non-resectable
distant metastases with or without primary colorectal tumor resection as a primary treatment in terms
of postoperative mortality and overall survival (OS).
Patients and methods: The clinicopathological data of 188 CRC patients with non-resectable distant
metastases was analyzed. All patient data were collected prospectively. Colorectal tumor was resected in
121 patients (64.3%). KaplaneMeier method was used for calculation and plotting of the OS curves of the
patient groups, and log-rank test was used for the comparison of the survival curves. The relative
importance of the prognostic features was investigated using the Cox proportional hazards model.
Results: In the whole series and in the patient group undergoing emergency surgical intervention,
mortality rate was lower in patients having colorectal tumor resection compared with non-resected
patients, with differences approaching the signiﬁcance level (p ¼ 0.072 and p ¼ 0.076, respectively).
Median OS time was signiﬁcantly longer in resection group (11.0 months), compared with non-resection
group (5.5 months) (p < 0.001); in the multivariate Cox analysis colorectal tumor resection had inde-
pendent prognostic signiﬁcance (p < 0.001).
Conclusion: Resection of colorectal tumor in primary CRC patients with non-resectable distant metastasis
gives signiﬁcant survival advantage without increasing postoperative mortality compared with non-
resection.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Of patients with primary colorectal carcinoma (CRC), approxi-
mately 20% present with distant metastasis at the time of diagnosis
[1e3]. Only 10e30% of patients with distant metastasis (stage IV
disease according to American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) tumor (T)- node
(N)- metastasis (M) classiﬁcation) [4] can have potentially curative
resection of the primary carcinoma and the distant metastasis [5e8].
Currently, a palliative resection of the primary colorectal tumor
before initiation of systemic therapy is frequently performed [2e9].
There are different approaches regarding the resection of the pri-
mary CRC in patients with non-resectable distant metastases and
asymptomatic or minimally symptomatic colorectal tumor, withoutker).
by Elsevier Ltd. All rights reservedcomplications requiring urgent surgical intervention (obstruction,
perforation, intractable bleeding). Some authors suggest that resec-
tion of colorectal tumor has advantages compared to non-resection,
such as prolonging the survival [1,5,10e13], prevention of future
complications related to the primary tumor [3,14,15], and psycho-
logical support to the patient [14]. Other authors suggest that this
approach may have been correct in the past, but treatment with
current chemotherapeutic (irinotecan, oxaliplatin) and biologic tar-
geted therapy (bevacizumab, cetuximab) agents can provide similar
or longer survival compared to colorectal tumor resection [1,7,15e
17]; that in some patients distant metastases may turn out to be
potentially curable by resection [15,18]; that the patient would be
spared the morbidity and mortality associated with primary surgery
[1,5,8]. Furthermore, they point that adjuvant therapy may be
delayed or may not be applied as a result of surgery [3,8,17].
In this study, patients with primary CRC and non-resectable
distant metastases with or without primary colorectal tumor.
Table 1
Clinicopathological and treatment features of the patients.
Feature Resection group Non-resection group p
n % n %
Gender 0.149
Female 43 35.5 31 46.3
Male 78 64.5 36 53.7
Age, years 0.410
Mean 57.3 59.0
Median 60.0 60.0
Range 21e87 26e83
Age, years 0.329
<70 99 81.8 50 74.6
70 22 18.2 17 25.4
Tumor site 0.008
Colon 75 62.0 28 41.8
Rectum 46 38.0 39 58.2
Tumor size, cm
5 53 43.8
>5 68 56.2
T stage
T2-T3 13 10.7
T4 108 89.3
Nodal status
Negative 19 15.7
Positive 102 84.3
Histological type 0.284
Non-mucinous 109 90.1 56 83.6
Mucinous 12 9.9 11 16.4
Distant metastasis <0.001
M1a 98 81.0 27 40.3
M1b 23 19.0 40 59.7
Surgery 0.824
Elective 104 86.0 56 83.6
Urgent 17 14.0 11 16.4
Adjuvant chemotherapy 0.040
Yes 73 60.3 30 44.8
No 48 39.7 37 55.2
Adjuvant radiotherapy 0.439
Yes 21 17.4 8 11.9
No 100 82.6 59 88.1
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postoperative mortality and overall survival (OS).
2. Patients and methods
2.1. Patients
Between January 1993 and December 2004, 1255 patients were
operated for primary CRC, with no past or concurrent malignancy
otherwise. Distant metastases were present in 208 (16.5%) of the
patients. Sixteen patients who had potentially curative resection of
the colorectal tumor and the distant metastases, and four patients
who received preoperative chemotherapy were not included in the
study. Thus, our series consisted of 188 patients with non-
resectable distant metastases. Colorectal tumor was resected in
121 patients (64.3%) in the series depending on the intraoperative
ﬁndings and the surgeon’s preference (resection group: segmental
colectomy, 74 patients; subtotal colectomy, 1 patient; low-anterior
resection, 30 patients; abdominoperineal resection,16 patients). No
resection was performed in 67 patients (35.7%) (non-resection
group: diverting stoma, 47 patients; enteric bypass, 11 patients;
exploration only, 9 patients). Elective surgerywas performed in 160
patients in the series who were either asymptomatic or had minor
symptoms, while emergency surgery was performed in 28 patients
who had symptoms requiring urgent surgical intervention (com-
plete obstruction, 27 patients; perforation, 1 patient).
Of clinicopathological features, colorectal wall invasion and
metastatic sites [M1a (metastasis conﬁned to one organ or site),
M1b (metastases in more than one organ/site or the peritoneum)]
were grouped according to the TNM classiﬁcation [4]. Metastatic
sites were determined by preoperative imaging and intraoperative
ﬁndings. Tumor size, wall invasion and lymph node status were
determined by pathological examination in the resection group
only. 5-ﬂuorouracyl-based chemotherapy was used in all patients
receiving adjuvant chemotherapy. Patients who received at least
two cycles of chemotherapy were considered to have received
adjuvant chemotherapy. All patient clinicopathological data were
collected prospectively, taking advantage of the Oncology Clinic
records of our hospital regarding adjuvant therapy. Survival data of
the patients discharged from the hospital after surgery were
collected by phone interviews with the patient or patient’s rela-
tives. All the patients died by reason of cancer.
Postoperative mortality was deﬁned as death occurring in hos-
pital or within 30 days. OS was deﬁned as the period starting from
the date of surgery until death. Patients with postoperative mor-
tality were not included in the survival analysis.
2.2. Statistics
The chi-square test was used to evaluate the differences be-
tween proportions and Student’s t-test was used to evaluate the
continuous data for comparisons of the clinicopathological features
of the patient groups. KaplaneMeier method was used for calcu-
lation and plotting of the OS curves of the patient groups, and log-
rank test was used for the comparison of the survival curves. The
relative importance of the prognostic features was investigated
using the Cox proportional hazards model. All comparisons were
two-tailed. p values less than 0.05 were considered to be statisti-
cally signiﬁcant. All statistical analyses were performed using SPSS
version 17.0 (SPSS, Inc., Chicago, IL).
3. Results
Table 1 presents clinicopathological and treatment features of
the patients. Resection and non-resection groups were notsigniﬁcantly different in terms of gender, age, histological type,
emergent or elective surgery, and adjuvant radiotherapy. The rate
of colon tumor (p ¼ 0.008), M1a distant metastasis (p < 0.001), and
adjuvant chemotherapy use (p ¼ 0.040) was signiﬁcantly higher in
the resection group, compared with the non-resection group.
Table 2 presents the organs/sites of distant metastasis. Distant
metastasis was present in a single organ/site in 137 patients, mul-
tiple organs/sites in 51 patients.
Mortality developed in 24 (12.7%) patients. Table 3 presents the
relationship between clinicopathological factors, surgical method
and mortality. Mortality rate was higher in patients aged 70 years
and above compared to patients under 70 years of age; the differ-
ence was near to the limit of signiﬁcance (p ¼ 0.058). In the whole
series and in the patient group undergoing emergency surgical
intervention, mortality rate was lower in patients having colorectal
tumor resection compared with non-resected patients, with dif-
ferences approaching the signiﬁcance level (p ¼ 0.072 and
p ¼ 0.076, respectively).
Median OS times according to clinicopathological and treatment
features in the whole series are presented in Table 4. Median sur-
vival timewas signiﬁcantly longer in resection group (11.0 months),
compared with non-resection group (5.5 months) (p < 0.001)
(Fig. 1); in the multivariate Cox analysis colorectal tumor resection
had independent prognostic signiﬁcance (p < 0.001) (Table 5).
Among 143 patients having elective surgery, median OS time was
signiﬁcantly longer in the resection group (95 patients, 11.0
months) compared with the non-resection group (48 patients, 6.0
Table 4
Median overall survival time according to clinicopathological and treatment
features.
Feature No. of patients Median time (months) p
Gender 0.778
Female 62 9.5
Male 102 6.5
Age, years 0.286
<70 134 8.5
70 30 7.0
Tumor site 0.864
Colon 89 7.0
Rectum 75 8.5
Histological type 0.368
Non-mucinous 142 8.5
Mucinous 22 7.0
Distant metastasis 0.108
M1a 111 10.0
M1b 53 6.0
Surgery 0.508
Elective 143 8.5
Urgent 21 6.5
Resection of primary tumor <0.001
Yes 110 11.0
Table 2
Site of distant metastases.
Site n (total 188) %
Liver 156 82.9
Peritoneal surface 48 25.5
Omentum 25 13.3
Nonregional lymph node 19 10.1
Ovary 5 2.6
Lung 3 1.6
Spleen 2 1.0
Brain 2 1.0
Kidney 1 0.5
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resection had independent prognostic signiﬁcance (relative risk for
non-resection group ¼ 2.18; 95% conﬁdence interval ¼ 1.39e3.40;
p ¼ 0.001). A separate survival analysis was conducted on the
resection group to investigate the effect of histopathological factors
on survival in stage IV disease; tumor size (p¼ 0.866), wall invasion
depth (p ¼ 0.870) and node status (p ¼ 0.968) had no effect on
survival.No 54 5.5
Adjuvant chemotherapy <0.001
Yes 103 12.5
No 61 3.5
Adjuvant radiotherapy 0.009
Yes 29 13.0
No 135 6.04. Discussion
In our study, comparison of postoperative mortality between
stage IV disease patients with resected and non-resected colorectal
tumor yielded lower mortality rates in patients with resected
colorectal tumor in the whole series and in the patient group
having emergent surgical intervention, with a nearly signiﬁcant
difference. In our series postoperativemortality ratewas 8.7% in the
patient group undergoing elective resection; this rate was reported
as 1.6% [11], 4.7% [3] and 8.5% [1] in some other studies. In our study,
OS of primary CRC patients with non-resectable distant metastasis
having colorectal tumor resection was signiﬁcantly better
compared with the non-resection group in the whole series (me-
dian OS 11.0 months vs 5.5 months, respectively) and in the elective
surgery group (median OS 11.0months vs 6.0months, respectively),
and resection of colorectal tumor had independent prognostic
signiﬁcance in the multivariate analysis. Various studies reported
signiﬁcantly better prognosis in all stage IV CRC patients with
resected colorectal tumor compared to non-resected patients, with
a median OS of 11.0e12.5 months in resection groups and 3.0e4.6Table 3
Postoperative mortality according to clinicopathological and treatment features.
Feature No. of patients Mortality (n) Mortality (%) p
Gender 0.358
Female 74 12 16.2
Male 114 12 10.5
Age, years 0.058
<70 149 5 10.1
70 39 9 23.1
Tumor site 0.877
Colon 103 14 13.6
Rectum 85 10 11.8
Distant metastasis 0.500
M1a 125 14 11.2
M1b 63 10 15.9
Surgery, whole series 0.072
Resection 121 11 9.1
Non-resection 67 13 19.4
Surgery, elective 0.404
Resection 104 9 8.7
Non-resection 56 8 14.3
Surgery, urgent 0.076
Resection 17 2 11.8
Non-resection 11 5 45.5months in non-resection groups [1,5,10,12]. In the patient group
having elective surgery, resection of colorectal tumor resulted in
signiﬁcantly longer survival compared with non-resection (median
OS 11.7months vs 5.2months, respectively) [1]; (16.0months vs 9.0
months, respectively) [11]. In a study including patients with rectal
cancer only, survival was signiﬁcantly better in patients having
resection of the primary tumor compared with non-resection pa-
tients [13].
Similarly, survival was found to be signiﬁcantly better in the
resection group compared with the non-resection group in some
series which included patients with non-resectable distant
metastasis as well as patients with no distant metastasis, but local
residual disease following colorectal tumor resection [9,19,20].
While, other studies found no signiﬁcant survival difference be-
tween patients having and not having colorectal tumor resection
[15,16].
When prognosis is compared between patients undergoing
resective and non-resective surgery, there is a high probability of
bias in terms of patient selection, since non-resective procedures
are generally applied on patients with poor general condition or
patients with more advanced disease [1,3,20,21]. One evidence for
this may be the ﬁnding in our study and certain other studies
showing higher postoperative mortality rates in patients having a
theoretically less-invasive intervention such as non-resection sur-
gery compared to patients having colorectal tumor resection
[19,20].
The reviews stated that in the absence of prospective random-
ized clinical trials, it would be difﬁcult to determine the optimal
management of primary CRC patients with non-resectable distant
metastasis; however, stated that it would appear that asymptom-
atic patients without an extensive metastatic load and with
reasonable performance status may beneﬁt from resection of
colorectal tumor [22,23]. A metaanalysis stated that palliative
resection of the primary tumor in asymptomatic or minimally
symptomatic patients with stage IV CRC is associated with a sig-
niﬁcant improvement in survival; and that resection of the primary
Fig. 1. Overall survival rates of the patients with non-resectable distant metastases
who did (110 patients) or did not (54 patients) undergo resection of primary colorectal
carcinoma in the whole series (p < 0.001).
Fig. 2. Overall survival rates of the patients with non-resectable distant metastases
undergoing elective surgery with (95 patients) or without (48 patients) resection of
primary colorectal carcinoma (p < 0.001).
N. Duraker et al. / International Journal of Surgery 12 (2014) 737e741740tumor decreases the likelihood of intestinal complications and
avoids the need for emergency procedures [24].
A review stated that for patients with stage IV incurable colo-
rectal cancer, resection of the asymptomatic primary tumorTable 5
Cox proportional hazards model analysis of the clinicopathological and treatment
features in the whole series.
Feature Relative risk 95% CI p
Gender 0.321
Female 1.00
Male 1.18 0.85e1.64
Age, years 0.110
<70 1.00
70 0.70 0.46e1.08
Tumor site 0.649
Colon 1.00
Rectum 1.09 0.75e1.56
Histological type 0.810
Non-mucinous 1.00
Mucinous 1.06 0.64e1.76
Distant metastasis 0.863
M1a 1.00
M1b 1.04 0.68e1.58
Surgery 0.912
Elective 1.00
Urgent 0.97 0.60e1.57
Resection of primary tumor <0.001
Yes 1.00
No 2.08 1.38e3.15
Adjuvant chemotherapy <0.001
Yes 1.00
No 4.78 3.24e7.06
Adjuvant radiotherapy 0.211
Yes 1.00
No 1.34 0.84e2.13
CI: conﬁdence interval.provides only minimal palliative beneﬁt, can give rise to major
morbidity and mortality and may potentially delay the adminis-
tration of systemic chemotherapy, thus in asymptomatic patients,
initial chemotherapy should be started and resection of the primary
tumor should be reserved for the patients who develop intestinal
complications [25].
In conclusion, resection of colorectal tumor in primary CRC
patients with non-resectable distant metastasis gives signiﬁcant
survival advantage without increasing postoperative mortality
compared with non-resection. However, prospective randomized
studies are needed to verify this ﬁnding, which may be a result of
patient selection bias.Ethical approval
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